Abstract P5-03-13: ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy

Although anti-HER2/neu antibody therapy combined with chemotherapy has achieved an outstanding effect, many patients with HER2-positive breast cancer still succumb due to therapeutic resistance. Understanding the mechanisms of therapeutic resistance is of vital importance. In this study, core needle biopsy tissue from HER2-positive patients was collected before neoadjuvant chemotherapy. Differentially expressed RNAs between pCR and non-pCR group have been identified through RNA-seq. Here we found that ERVMER34, an endogenous retroviral envelope protein was significantly inhibited in non-pCR group compared to pCR group. High ERVMER34 expression was associated with good overall survival both in TCGA database and our own patients cohort. Further study showed that ERVMER34 could be glycosylated and secreted to cell supernatant. The IC50 of paclitaxel and trastuzumab in HER2 positive breast cancer cells was decreased by ectopic overexpression of ERVMER34. Furthermore, RNA-seq, FACS assay and western blot revealed that ERVMER34 could promote cell apoptosis and sensitize therapy response through inhibiting mTOR pathway in HER2 positive breast cancer cells. Via mass spectrometry, TRIM21, an E3 ligase was found to interact with ERVMER34 and promoted its ubiquitination degradation. Taken together, these data suggest that ERVMER34 may severve as a novel biomarker to predict therapy response in HER2 positive breast cancer.

Citation Format: Chi Y, Ji W, Xiu B, Zhang Q, Wu J. ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-03-13.

Leaf-like Co-ZIF-L derivatives embedded on Co2AlO4/Ni foam from hydrotalcites as monolithic catalysts for toluene abatement

Herein, a series of distinctively monolithic catalysts were first synthesized by decorating leaf-like Co-ZIF-L derivatives on Co₂AlO₄ coral-like microspheres from CoAl layered double hydroxides (LDHs), which were coated on three-dimensional porous Ni foam. As a proof of concept application, toluene was chosen as a probe molecule to evaluate their catalytic performances over the as-synthesized catalysts. As a result, the L-12 sample derived from Co₂AlO₄@Co-Co LDHs displayed an excellent catalytic performance, cycling stability and long-term stability for toluene oxidation (T₉₉ = 272 °C, 33 °C lower than that of Co₂AlO₄ sample), where leaf-like Co-ZIF-L served as a sacrificial template to synthesize Co-Co LDHs. The improved catalytic performance was attributed to its distinctive structure, in which leaf-like Co-ZIF-L derivatives on Co₂AlO₄ resulted in its higher specific surface area, lower-temperature reducibility, rich surface oxygen vacancy and high valence Co³⁺ species. This work thus demonstrates a feasible strategy for the design and fabrication of hybrid LDHs/ZIFs-derived composite architectures, which is expected to construct other novel monolithic catalysts with hierarchical structures for other potential applications.

Abstract P4-01-08: Characterization of circulating tumor free DNA (ctDNA) obtained from patients with metastatic breast carcinoma (MBC) undergoing systemic therapies using comprehensive genomic profiling

Introduction:Therapeutic benefit from individual treatments in patients with MBC is limited to small subsets of patients and of short duration due to tumor heterogeneity. Novel molecular diagnostics including ctDNA has been shown to predict response or resistance and survival. However, the frequency of detection of actionable mutations using ctDNA is variable based upon tumor related factors and diagnostic platform sensitivity (e.g. ddPCR or NGS). We evaluated a novel NGS technology in the ability of detecting driver and clonal genomic abnormalities in samples from MBC patients. Moreover, we wanted to compare the new technology to another state-of-the-art, commercially available diagnostic ctDNA testing with similar sensitivity to demonstrate both are able to detect genomic abnormalities in MBC.

Methods: This study included 30 samples from 15 patients with stage III/IV BCa treated at NMH (2016-2017) and who received standard systemic treatments based on disease subtypes longitudinally characterized for ctDNA before or 3 months after systemic therapies respectively. ctDNA from clinical plasma samples was first analyzed using PredicinePLUS, a NGS-based assay (Predicine Inc) with a 180-gene panel for genomic alterations mutations. The results were then independently analyzed with Guardant360TM (Guardant Health), a 73-gene panel. Matched pairs variations between Guardant360TM and Predicine was compared by Wilcoxon signed-ranks test. The prognostic impact of ctDNA was tested through Cox regression.

Results: Genomic Alterations (SNVs, Indels and copy number variations) were detected on 43 genes by PredicinePLUS assay. All samples (100%) demonstrated at least 1 somatic alterations. There were 75 mutations detected within 29 genes, and the variant frequency of mutated genes ranges from 0.11% to 68.56%. Median variant frequency was around 3.42%. Key cancer related genes including TP53, ESR1, PIK3CA, PTEN and BRCA1, are frequently mutated. Copy number variation were detected on 18 genes, among which 15 genes showed copy number gain, including MYC, PIK3CA, CCND1, and 3 genes (ATM, BRCA1 and CDKN2A) with copy number loss. There were no significant difference of % ctDNA (P=0.3967) and number of variations (P=0.5) between results of Predicine and Guardant360TM, neither to the comparison of main detected alterations (BRCA1, ESR1, MYC, PIK3CA and TP53) with Guardant360TM and Predicine (P=1). Furthermore, results from Predicine indicated that there is correlation with treatment response and benefit. A significant decrease on variations in %ctDNA levels (P=0.028) and variations in the number of genomic variants (P=0.028) after systemic therapies, was associated with longer overall survival.

Conclusions: Our study describes a novel diagnostic platform with the ability to identify ctDNA mutation and copy number variations in patients with MBC receiving systemic therapy. We also confirm that when comparing ctDNA using NGS platforms with similar sensitivity, the results are robust and reproducible which indicates that these technologies can be reliably and routinely used as non-invasive method for monitoring response to systemic therapies and predict the prognosis in MBC.

Citation Format: Zhang Q, Gerratana L, Zhang Y, Flaum L, Gradishar W, Platanias L, Cristofanilli M. Characterization of circulating tumor free DNA (ctDNA) obtained from patients with metastatic breast carcinoma (MBC) undergoing systemic therapies using comprehensive genomic profiling [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-08.

Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype

Introduction: HER2 overexpression is observed on CTCs in advanced BC (ABC), but their significance is not known. We aimed to describe clinical, pathologic, and molecular associations with HER2 overexpression on CTCs in ABC patients (pts).

Methods: We conducted a retrospective analysis of data from ABC pts treated at Thomas Jefferson University and Northwestern University who had evaluation of CTCs and circulating tumor DNA (ctDNA). CTCs were enumerated with the CellSearch immunomagnetic kit (Menarini Silicon Biosystems), HER2 expression on CTCs was evaluated using the CellSearch CXC Kit, and ctDNA was analyzed using the Guardant360 NGS assay (Guardant Health). Associations with the presence of HER2+ CTCs were explored through univariate and multivariate logistic regression. Kruskal-Wallis testing evaluating HER2+ CTCs as a continuous variable was also conducted to confirm consistency of findings. Time to development of HER2+ CTCs was evaluated using Cox proportional hazards regression analysis.

Results: Baseline CTCs were evaluated in 209 pts (10% stage III, 90% stage IV) of whom 41% had no detectable CTCs, 23% had 1-4 CTCs, and 36% had >5 CTCs (stage IV aggressive). Twelve percent had CTC clusters. At least 1 HER2+ CTC was seen in 33% of pts at baseline draw. Of 39 patients with HER2+ BC, only 18% had HER2+ CTCs. Of patients with HER2+ CTCs, 55% had hormone receptor positive BC, 28% had triple negative BC, and 18% had HER2+ BC. On univariate logistic analysis, BC subtype or HER2 status was not associated with the presence of HER2+ CTCs. IBC pts represented 52% of pts and were less likely to have HER2+ CTCs (OR 0.40 95% CI 0.19-0.84). Bone metastases were associated with an increased likelihood of HER2+ CTCs (OR 2.46, 95% CI 1.12-5.38); however, other sites of metastases and number of metastatic sites were not correlated with HER2+ CTCs. Aggressive disease features including >5 CTCs and presence of CTC clusters were strongly associated with HER2+ CTCs (OR 15.72, 95% CI 6.89-35.8 and 8.97, 95% CI 3.23-24.89, respectively). Of 168 pts with ctDNA analysis, ERRB2 aberrations were seen in 22% of pts and were significantly associated with HER2+ CTCs (OR of 3.74, 95% CI 1.45-9.63). On multivariate analysis, the associations with >5 CTCs and ERBB2 alterations in ctDNA remained statistically significant. The associations of HER2+ CTCs with bone disease, >5 CTCs, CTC clusters, and ERBB2 alterations in ctDNA, and the inverse relationship with IBC were consistent when HER2+ CTCs were evaluated as a continuous variable with Kruskal-Wallis testing. Among pts without HER2+ CTCs at baseline, the time to detection of HER2+ CTCs correlated with the presence of bone metastases (HR 3.40, 95% CI 1.14-10.19), >5 CTCs (3.77, 95% CI 1.33-10.70), and visceral disease (HR 3.00, 95% CI 1.07-8.44).

Conclusions: HER2+ CTCs are common in ABC, independent of HER2 status of the tumor, and, in fact, common in the luminal BC. HER2+ CTCs were also strongly associated with CTC characteristics of aggressive disease with poor survival (CTCs clusters and >5 CTCs) and ERBB2 aberrations in ctDNA. Further studies will be investigating the role of HER2+ CTCs in endocrine resistance and the potential of anti-HER2 therapy in this unique CTC-defined setting.

Citation Format: Shah AN, Gerratana L, Davis AA, Zhang Q, Zhang Y, Rossi G, Wang C, Strickland K, Yang H, Flaum L, Abu-Khalaf M, Behdad A, Ye Z, Platanias L, Gradishar WJ, Cristofanilli M. HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-19.

Abstract P3-01-10: Associations between plasma Interleukin 2 (IL-2) and HER2 expression in circulating tumor cell (CTC) and MYC alterations in circulation tumor DNA (ctDNA) open a new insight on immune microenvironment for patients with metastatic breast cancer (MBC)

Introduction: Overexpression of HER2 has been reported to be associated with metastasis and poor prognosis of patients with MBC. We reported in AACR 2018 that HER2 overexpression is associated with CTC-cluster. Preclinical data suggested that MYC and HER2 cooperate to drive stem cell phenotype and poor prognosis in MBC (Nair R). Furthermore, IL-2 upregulates the transcription of MYC (Grigorieva I) and gets involved into its alterations. We reasoned that further understanding of interactions of HER2 in CTC and MYC will be important to elucidate the mechanism of metastasis of MBC. Herein, we report a significant correlation between the plasma IL-2 level and HER2 expression in CTCs, and the IL-2 related MYC ctDNA alterations in MBC.

Methods: This study enrolled 43patients with stage III/IV BCa at the Northwestern Memorial Hospital (2016-2017) that had longitudinally detection of CTCs and ctDNA. Whole blood samples (7.5ml/each) were collected for CTCs enumeration by using CELLTRACKS ANALYZERII® System (Menarini) contains antibodies of anti-EpCAM for capturing CTCs, anti-CK-PE for epithelial cells, DAPI for nucleus, anti-CD45-APC for leukocytes and anti-HER-2/neu-FLU. The CTCs were classified based on phenotype as CK+, EpCAM+, DAPI+ and CD45-.Plasma ctDNA was analyzed using the Guardant360 TM NGS-based assay (Guardant Health), a 73 genes panel. ELISA for IL-2 was performed by using patients' plasma. Database of IL-2, HER2, CTCs and ctDNA was linked with clinical database and analyzed by Kruskal-Wallis test.

Results: CTCs ≥ 5 were found in 20 patients (46%). There were 15 patients that had HER2 negative CTCs (Group 1), and 5 patients had HER2 positive (Group 2) CTCs. The level of IL-2 was much higher in Group 1 (88.17pg) compared to Group 2 (66.81pg), indicating that patients with HER2 positive CTCs have significant lower IL-2 than patients with negative CTCs (P=0.02). Meanwhile, ctDNA MYC alterations were detected in 10 patients (including 1 L114R mutation, 7 CNV and 2 SNV) who have the average IL-2 level as 94.00pg. There were 11 patients without any alterations of MYC had average IL-2 level of 70.17pg, which indicated that patients with alterations in the ctDNA MYC have significant higher level of IL-2 in compared with patients without MYC alterations (P=0.02).

Conclusions: Findings of the correlation between overexpression of HER2 in CTCs and low IL-2 level indicated that low immunity may contribute to more aggressive MBC. And the higher level of IL-2 appear associated predominantly with MYC genomic alterations indicated that overexpression of MYC may also stimulate the immune response by upregulating IL-2 via a reverse feedback pathway. We postulated that increasing IL-2 suppresses the HER2 expression in CTC and breaks cooperation between HER2 and MYC. Although the interactions between them still unknown, our results suggest that IL-2 related immune microenvironment acts as a key player to suppress HER2- and MYC-mediated progress in MBC, including the formation of CTC-cluster. Monitoring and administration of IL-2 may benefit pretreated MBC patients and predict disease metastasis.

Citation Format: Zhang Q, Gerratana L, Zhang Y, Flaum L, Shah A, Davis A, Behdad A, Gradishar W, Platanias L, Cristofanilli M. Associations between plasma Interleukin 2 (IL-2) and HER2 expression in circulating tumor cell (CTC) and MYC alterations in circulation tumor DNA (ctDNA) open a new insight on immune microenvironment for patients with metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-01-10.

Abstract P4-01-14: Association between interleukin 2 (IL-2) and circulating tumor DNA (ctDNA) is a novel biomarker for patients with metastatic breast cancer (BCa) after systemic therapies

Introduction: The detection and monitoring of ctDNA in metastatic breast cancer showed ability to predict treatment resistance and outcome. But the mechanisms has been a challenge to clinicians. Immune escape and immune tolerance has also been reported to cause BCa progress. Herein, we report a novel finding of the association between plasma IL-2 and the ctDNA in advanced BCa patients who received the systemic therapies, and it is potential utilization in clinic.

Methods: This study enrolled 43 patients with stage III/IV BCa at the Northwestern Memorial Hospital (2016-2017) that had longitudinally detection of ctDNA and circulating tumor cells (CTCs) before (baseline, BL) or 3 months after (first evaluation, FE) systemic therapies respectively. Duplicate whole blood samples (7.5ml/each) were collected in EDTA tubes from these patients. Plasma ctDNA was analyzed using the Guardant360 NGS-based assay (Guardant Health) and CTC enrichment and enumeration were performed in FDA approved semi-automated fluorescence CELLTRACKS ANALYZERII® System (Menarini Silicon Biosystems) by using CELLSEARCH® CXC Kit (Menarini). ELISA (Fisher) for IL-2 was performed by using patients' plasma. Database of IL-2, ctDNA and CTCs was generated and linked with clinical database. Kruskal-Wallis test was used for statistics. We previously reported cut-off of 5.7 was used to dichotomize the prognostic value of ctDNA percentage (%ctDNA) in 2018 ASCO. Matched pairs variations between IL2 levels at BL and at FE were tested through Wilcoxon signed-ranks test. Associations between %ctDNA and IL2 levels were explored through Kruskal-Wallis test. The prognostic impact of IL2 was tested through Cox regression.

Results: CTCs ≥ 5 were found in 23 patients at BL and 21 patients in FE respectively. There were 12 patients that had increase CTCs, and 31 patients with similar or less CTCs FE after systemic therapies. Decreased in CTCs was associated with increased IL-2 (P=0.004).The FE analysis showed that IL-2 dropped significantly in patients with CTC stably ≥5 (from 95.84pg to 79.46pg) after therapies (P<0.001). Furthermore, baselineIL-2 levels were significantly higher in patients with % ctDNA levels ≥5.7 (97.15pg) compared to patients with %ctDNA levels <5.7 (68.64pg) (P=0.0027). No other associations were highlighted in respect to age or number of ctDNA alterations. There was no significant variations between BL and FE levels of IL2 were observed according to BCa subtypes nor in respect to baseline %ctDNA ≥5.7 or CTCs ≥5. Compared with low level of BL IL-2 (<78.3pg) group, high level of BL IL-2 (≥78.3pg) had a significant negative impact on overall survival (OS) (P=0.037) in univariate analysis.

Conclusions: Our findings indicated that aggressive BCa with high level ctDNA mutation are associated with high level of IL-2 and immune response in patients with advanced disease. In addition we confirm a reverse correlation between change of IL-2 and change of CTCs potentially indication of immune escape. In summary, the study shows a dynamic relation between IL-2 level and tumor burden (ctDNA) and immune escape (CTCs) suggesting another potential biomarker to monitor interaction between tumor and immune environment.

Citation Format: Zhang Q, Gerratana L, Zhang Y, Flaum L, Shah A, Davis A, Behdad A, Gradishar W, Platanias L, Cristofanilli M. Association between interleukin 2 (IL-2) and circulating tumor DNA (ctDNA) is a novel biomarker for patients with metastatic breast cancer (BCa) after systemic therapies [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-14.

Abstract P5-17-02: Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature

Background: The biological characteristics conferring Inflammatory BC's (IBC) distinctive and aggressive clinical features are currently not fully clarified. The aim of this study is to dissect IBC's biology through the integration of DNA and CTC-based circulating biomarkers.

Methods: This study retrospectively analyzed 251 Advanced BC (ABC) patients (pts) treated and longitudinally characterized for CTCs and circulating tumor DNA (ctDNA) at Thomas Jefferson University (Philadephia, PA) and Northwestern University (Chicago, IL). CTCs were enumerated through CellSearch (Menarini Silicon Biosystems), and characterized for HER2 expression using the CellSearch CXC Kit, while ctDNA was analyzed using the Guardant360 NGS assay (Guardant Health) and its percentage (%ctDNA) was classified based on the previously reported cut-off of 5.7% (Gerratana et al 2018). A subset of 117 pts was further characterized for circulating cell-free DNA (ccfDNA) through Qubit® dsDNA HS quantitation Assay (Thermo Fisher Scientific) and quantitative real-time PCR assay for ALU DNA repeats on chromosome 1.Associations between clinical characteristics, CTCs-derived biomarkers and IBC were explored through Fisher's exact test; survival was tested though Cox regression and log-rank test.

Results: Of the total 251 pts, 115 were diagnosed with IBC. Among the 117 patients characterized for ccfDNA, 70 had IBC. Median ccfDNA was 1.59 for IBC (IQR 1.02-3.19) and 2.37 for non-IBC (nIBC) (IQR 1.13-3.52), P=0.27. Consistent results were observed for %ctDNA levels (median value: 2 vs 1.6). The impact on OS of ccfDNA after log transformation was significant for the total population (HR 1.73 95%CI: 1.11-2.69) but not in IBC pts (HR 1.40 95%CI: 0.84-2.34). On the other hand, ctDNA high pts had a significantly worse OS (nIBC: HR 5.34 95%CI: 1.70-18.81 P=0.004; IBC: HR 4.05 95%CI: 1.91-8.58 P< 0.001). In the ctDNA high subgroup no differences in total number of CTCs were observed between IBC and nIBC, while significantly lower CTCs were observed in ctDNA low IBC pts (P=0.0097). The ctDNA low IBC subgroup had a higher incidence of HER2 positive BC (P=0.003) and a significantly lower incidence of CTCs clusters (P=0.006), HER2 positive CTCs (P=0.041). Notably, no associations were observed with stage at baseline, number of metastatic sites, liver, lung and visceral involvement. On the other hand, the ctDNA_high IBC subgroup was characterized by a lower incidence in liver, bone and visceral involvement (P=0.017, P=0.014 and P=0.03 respectively) and a marginally high incidence in soft tissue involvement (0.084). Moreover, IBC diagnosis conferred a significantly worse prognosis only in the ctDNA low subgroup (OS at 12 months nIBC: 100% vs IBC: 70%; P=0.049), while no differences were observed in the ctDNA_high subgroup (OS at 12 months nIBC: 29% vs IBC: 26%; P=0.767).

Conclusion: ctDNA is able to stratify BC according to aggressiveness independently from the sites and type of metastases, both in the IBC and nIBC subgroups. IBC has a distinctive CTCs/ctDNA-based signature, in particular ctDNAlow pts have a lower incidence of HER2 positive CTCs and CTC clusters. This signature is probably due to predominant lymphatic metastatic spread and aggressive phenotype.

Citation Format: Gerratana L, Zhang Q, Wang C, Shah A, Davis AA, Ye Z, Zhang Y, Abu-Khalaf M, Flaum L, Strickland K, Rossi G, Behdad A, Gradishar W, Platanias L, Yang H, Cristofanilli M. Dissecting the biology of inflammatory breast cancer (BC) through cell free DNA and a circulating tumor cells (CTC)-derived signature [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-17-02.

Two-Photon Image Tracking of Neural Stem Cells via Iridium Complexes Encapsulated in Polymeric Nanospheres

Iridium(III) complexes have been shown to be promising probes in two-photon imaging to real-time track the transplanted cells in stem-cell-based therapy. Here, we report on polymeric nanocapsules loaded with red phosphorescence dye of bis(2-methyldibenzo[f,h]quinoxaline) (acetylacetonate) iridium(III) (Ir(MDQ)₂acac) with excellent stability created by the double emulsion method. The Ir(MDQ)₂acac nanocapsules present high biocompatibility and an efficient fluorescent labeling rate when incubated with cultured mouse neural stem cells (NSCs). More importantly, the Ir(MDQ)₂acac nanocapsules had both one- and two-photon imaging properties with stable phosphorescence lasting for 72 h. Furthermore, data from in vivo tracking in nude mice demonstrated that the photoluminescence from Ir(MDQ)₂acac nanocapsules in NSCs could be stably monitored for up to 21 days. Our data shed light on the potential clinical application of iridium complexes encapsulated in polymeric nanospheres for two-photon imaging in real-time tracking of the transplanted stem cells.

Metal-free visible light photoredox enables generation of carbyne equivalents via phosphonium ylide C-H activation

Carbyne, an interesting synthetic intermediate, has recently been generated from hypervalent iodine precursors via photoredox catalysis. Given the underexplored chemistry of carbyne, due to the paucity of carbyne sources, we are intrigued to discover a new source for this reactive species from classical reagents - phosphonium ylides. Our novel strategy employing phosphonium ylides in an olefin hydrocarbonation reaction features a facile approach for constructing carbon-carbon bonds through metal-free and benign reaction conditions. Moreover, the hydrocarbonation products were delivered in a highly regioselective manner.

Serum indoxyl sulfate is associated with mortality in hospital-acquired acute kidney injury: a prospective cohort study

BACKGROUND

Protein-bound uremic toxins are associated with poor outcomes in patients with chronic kidney disease. The aim of this study is to investigate the relationship between indoxyl sulfate (IS), a protein-bound solute, and 90-day mortality in patients with acute kidney injury.

METHODS

Adults with hospital-acquired AKI (HA-AKI) were enrolled in this prospective cohort study between 2014 and 2015, according to the KDIGO creatinine criteria. The primary end point was all-cause death during follow-up.

RESULTS

The mean serum IS level in patients with HA-AKI was 2.74 ± 0.75 μg/ml, which was higher than that in healthy subjects (1.73 ± 0.11 μg/ml, P < 0.001) and critically ill patients (2.46 ± 0.35 μg/ml, P = 0.016) but was lower than that in patients with chronic kidney disease (3.07 ± 0.31 μg/ml, P < 0.001). Furthermore, serum IS levels (2.83 ± 0.55 μg/ml) remained elevated in patients with HA-AKI on the seventh day after AKI diagnosis. Patients with HA-AKI were divided into the following two groups according to the median serum IS level: the low-IS group and the high-IS group. A total of 94 (35.9%) patient deaths occurred within 90 days, including 76 (29.0%) in the low-IS group and 112 (42.7%) in the high-IS group (P = 0.019). Kaplan-Meier analysis revealed that the two groups differed significantly with respect to 90-day survival (log-rank P = 0.007), and Cox regression analysis showed that an IS level ≥ 2.74 μg/ml was significantly associated with a 2.0-fold increased risk of death (adjusted hazard ratio [HR], 2.92; 95% confidence interval [CI], 1.76 to 4.86; P < 0.001) compared with an IS level < 2.74 μg/ml.

CONCLUSIONS

Serum IS levels were significantly elevated in patients with HA-AKI compared to those in healthy subjects and critically ill patients and were associated with a worse prognosis of HA-AKI.

TRIAL REGISTRATION

www.clinicaltrials.gov NCT 00953992. Registered 6 August 2009.

Nanocellulose-Enabled, All-Nanofiber, High-Performance Supercapacitor

Nanocellulose has been used as a sustainable nanomaterial for constructing advanced electrochemical energy-storage systems with renewability, lightweight, flexibility, high performance, and satisfying safety. Here, we demonstrate a high-performance all-nanofiber asymmetric supercapacitor (ASC) assembled using a forest-based, nanocellulose-derived hierarchical porous carbon (nanocellulose carbon, HPC) anode, a mesoporous nanocellulose membrane separator (nanocellulose separator), and a NiCo₂O₄ cathode with nanocellulose carbon as the support matrix (nanocellulose cathode, HPC/NiCo₂O₄). HPC has a three-dimensional porous structure comprising interconnected nanofibers with an ultrahigh surface area of 2046 m² g^-1. When integrated with the mesoporous feature of the nanocellulose membrane separator, these properties facilitate the quick delivery of both ions and electrons even with a thick (up to several hundreds of micrometers) and highly loaded (5.8 mg cm^-2) ASC design. Consequently, the all-nanofiber ASC demonstrates a high electrochemical performance (64.83 F g^-1 (10.84 F cm^-3) at 0.25 A g^-1 and 32.78 F g^-1 or 5.48 F cm^-3 at 4 A g^-1) that surpasses most cellulose-based ASCs ever reported. Moreover, the nanocellulose components promise renewability, low cost, and biodegradability, thereby presenting a promising direction toward high-power, environmentally friendly, and renewable energy-storage devices.

Facile Fabrication of Size-Tunable Core/Shell Ferroelectric/Polymeric Nanoparticles with Tailorable Dielectric Properties via Organocatalyzed Atom Transfer Radical Polymerization Driven by Visible Light

An unconventional but facile approach to prepare size-tunable core/shell ferroelectric/polymeric nanoparticles with uniform distribution is achieved by metal-free atom transfer radical polymerization (ATRP) driven by visible light under ambient temperature based on novel hyperbranched aromatic polyamides (HBPA) as a functional matrix. Cubic BaTiO3/HBPA nanocomposites can be prepared by in-situ polycondensation process with precursors (barium hydroxide (Ba(OH)2) and titanium(IV) tetraisopropoxide (TTIP)) of ferroelectric BaTiO3 nanocrystals, because precursors can be selectively loaded into the domain containing the benzimidazole rings. At 1200 °C, the aromatic polyamide coating of cubic BaTiO3 nanoparticles are carbonized to form carbon layer in the inert environment, which prevents regular nanoparticles from gathering. In addition, cubic BaTiO3 nanoparticles are simultaneously transformed into tetragonal BaTiO3 nanocrystals after high temperature calcination (1200 °C). The outer carbon shell of tetragonal BaTiO3 nanoparticles is removed via 500 °C calcination in air. Bi-functional ligand can modify the surface of tetragonal BaTiO3 nanoparticles. PMMA polymeric chains are growing from the initiating sites of ferroelectric BaTiO3 nanocrystal surface via the metal-free ATRP technique to obtain core/shell ferroelectric BaTiO3/PMMA hybrid nanoparticles. Changing the molar ratio between benzimidazole ring units and precursors can tune the size of ferroelectric BaTiO3 nanoparticles in the process of polycondensation, and the thickness of polymeric shell can be tailored by changing the white LED irradiation time in the organocatalyzed ATRP process. The dielectric properties of core/shell BaTiO3/PMMA hybrid nanoparticles can be also tuned by adjusting the dimension of BaTiO3 core and the molecular weight of PMMA shell.

Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer

Combination therapy is a promising treatment for certain advanced drug-resistant cancers. Although effective inhibition of various tumor cells was reported in vitro, combination treatment requires improvement in vivo due to uncontrolled ratiometric delivery. In this study, a tumor-targeting lipodisk nanoparticle formulation was developed for ratiometric loading and the transportation of two hydrophobic model drugs, doxorubicin (DOX) and paclitaxel (PTX), in one single platform. Furthermore, a slightly acidic pH-sensitive peptide (SAPSP) incorporated into lipodisks effectively enhanced the tumor-targeting and cell internalization. The obtained co-loaded lipodisks were approximately 30 nm with a pH-sensitive property. The ratiometric co-delivery of two drugs via lipodisks was confirmed in both the drug-resistant MCF-7/ADR cell line and its parental MCF-7 cell line in vitro, as well as in a tumor-bearing mouse model in vivo compared with a cocktail solution of free drugs. Co-loaded lipodisks exerted improved cytotoxicity to tumor cells in culture, particularly to drug-resistant tumor cells at synergistic drug ratios. In an in vivo xenograft mouse model, the anti-tumor ability of co-loaded lipodisks was evidenced by the remarkable inhibitory effect on tumor growth of either MCF-7 or MCF-7/ADR tumors, which may be attributed to the increased and ratiometric accumulation of both drugs in the tumor tissues. Therefore, tumor-specific lipodisks were crucial for the combination treatment of DOX and PTX to completely exert a synergistic anti-cancer effect. It is concluded that for co-loaded lipodisks, cytotoxicity data in vitro could be used to predict their inhibitory activity in vivo, potentially enhancing the clinical outcome of synergistic therapy.

Photocatalytic degradation of deoxynivalenol over dendritic-like α-Fe₂O₃ under visible light irradiation

Deoxynivalenol (DON) is a secondary metabolite produced by Fusarium, which is a trichothecene mycotoxin. As the main mycotoxin with high toxicity, wheat, barley, corn and their products are susceptible to contamination of DON. Due to the stability of this mycotoxin, traditional methods for DON reduction often require a strong oxidant, high temperature and high pressure with more energy consumption. Therefore, exploring green, efficient and environmentally friendly ways to degrade or reduce DON is a meaningful and challenging issue. Herein, a dendritic-like α-Fe₂O₃ was successfully prepared using a facile hydrothermal synthesis method at 160 °C, which was systematically characterized by X-ray diffraction (XRD), high-resolution transmission electron microscopy (HRTEM), scanning electron microscopy (SEM), and X-ray photoelectron spectroscopy (XPS). It was found that dendritic-like α-Fe₂O₃ showed superior activity for the photocatalytic degradation of DON in aqueous solution under visible light irradiation (λ > 420 nm) and 90.3% DON (initial concentration of 4.0 μg/mL) could be reduced in 2 h. Most of all, the main possible intermediate products were proposed through high performance liquid chromatography-mass spectrometry (HPLC-MS) after the photocatalytic treatment. This work not only provides a green and promising way to mitigate mycotoxin contamination but also may present useful information for future studies.

[Associations between milk intake at breakfast and nutritional status of students attending the Nutrition Improvement Program for Rural Compulsory Education Students in 2016]

Objective: To investigate the association between milk intake at breakfast and nutritional status of students attending the Nutrition Improvement Program for Rural Compulsory Education Students (NIPRCES) in 2016, and to provide basic data for improving the nutritional status of the poor rural pupils. Methods: Using the multi-stage stratified random cluster sampling method, 22 315 students from grade three to nine from primary and junior high schools were randomly selected from the 50 key counties under the monitor programs, in 22 provinces of NNIPRCS. Questionnaire was used. Among all the students, with equal number of genders, morning fasting height and weight were measured by trained investigators. Status of nutrition was classified as malnutrition, normal, overweight/obesity, by age-specific height and BMI. Multivariate linear and logistic regression methods were used to analyze the relationship between milk consumption and the status of nutrition of the students. Results: Only 31.4% of the students that were on the monitoring programs would drink milk at breakfast. Proportions of milk intake at breakfast were higher in students from the western regions, in lower grades and in girls (P<0.05). The proportions of malnutrition and overweight/obesity were 11.0% and 10.0% respectively. After controlling factors as gender, age, ethnicity, region of residency and types of parental employment, students who drank milk at breakfast showed an average height of 0.4 cm taller than those who did not drink milk (P=0.001). However, no significant relationships were noticed between milk intake at breakfast and weight, malnutrition or overweight/obesity. Conclusion: Milk intake at breakfast seemed associated with the height of the students under study, suggesting that this program can be promoted, especially in students from the poor rural areas.

GDF11 Rejuvenates Cerebrovascular Structure and Function in an Animal Model of Alzheimer's Disease

Cerebral amyloid angiopathy (CAA) is present in up to 90% of patients with Alzheimer's disease (AD), and may interact with classical neuropathology to exacerbate cognitive decline. Since growth differentiation factor 11 (GDF11) can activate vascular remodeling, we tested its effects on cognitive function and neuroinflammatory changes of AD model mice. We intravenously administered GDF11 or vehicle daily to 12-month-old transgenic mice overexpressing the amyloid-β protein precursor (AβPP)/PS1). Cognitive function was monitored using the Morris water maze, and after conclusion of the treatment, we assessed the morphology and presence of inflammatory markers in the cerebral vasculature. Subchronic treatment of adult AβPP/PS1 mice with GDF11 rescued cognitive function and ameliorated cerebrovascular function. In particular, the de novo genesis of small blood vessels and the expression of vascular-related proteins were significantly higher than in the vehicle-treated AβPP/PS1 mice, whereas the expressions of the inflammatory markers Iba-1 and GFAP significantly decreased in proportion to the lower ratio of two forms of amyloid-β (Aβ40/42). Daily intravenous treatment with GDF11-injection can rejuvenate respects of cognition and cerebrovascular changes in AD mice.

Safety and accuracy of robot-assisted versus fluoroscopy-assisted pedicle screw insertion in thoracolumbar spinal surgery: a prospective randomized controlled trial

OBJECTIVE

The object of this study was to compare the safety and accuracy of pedicle screw placement using the TiRobot system versus conventional fluoroscopy in thoracolumbar spinal surgery.

METHODS

Patients with degenerative or traumatic thoracolumbar spinal disorders requiring spinal instrumentation were randomly assigned to either the TiRobot-assisted group (RG) or the freehand fluoroscopy-assisted group (FG) at a 1:1 ratio. The primary outcome measure was the accuracy of screw placement according to the Gertzbein-Robbins scale; grades A and B (pedicle breach < 2 mm) were considered clinically acceptable. In the RG, discrepancies between the planned and actual screw placements were measured by merging postoperative CT images with the trajectory planning images. Secondary outcome parameters included proximal facet joint violation, duration of surgery, intraoperative blood loss, conversion to freehand approach in the RG, postoperative hospital stay, and radiation exposure.

RESULTS

A total of 1116 pedicle screws were implanted in 234 patients (119 in the FG, and 115 in the RG). In the RG, 95.3% of the screws were perfectly positioned (grade A); the remaining screws were graded B (3.4%), C (0.9%), and D (0.4%). In the FG, 86.1% screws were perfectly positioned (grade A); the remaining screws were graded B (7.4%), C (4.6%), D (1.4%), and E (0.5%). The proportion of clinically acceptable screws was significantly greater in the RG than in the FG (p < 0.01). In the RG, the mean deviation was 1.5 ± 0.8 mm for each screw. The most common direction of screw deviation was lateral in the RG and medial in the FG. Two misplaced screws in the FG required revision surgery, whereas no revision was required in the RG. None of the screws in the RG violated the proximal facet joint, whereas 12 screws (2.1%) in the FG violated the proximal facet joint (p < 0.01). The RG had significantly less blood loss (186.0 ± 255.3 ml) than the FG (217.0 ± 174.3 ml; p < 0.05). There were no significant differences between the two groups in terms of surgical time and postoperative hospital stay. The mean cumulative radiation time was 81.5 ± 38.6 seconds in the RG and 71.5 ± 44.2 seconds in the FG (p = 0.07). Surgeon radiation exposure was significantly less in the RG (21.7 ± 11.5 μSv) than in the FG (70.5 ± 42.0 μSv; p < 0.01).

CONCLUSIONS

TiRobot-guided pedicle screw placement is safe and useful in thoracolumbar spinal surgery.Clinical trial registration no.: NCT02890043 (clinicaltrials.gov).

Construction of a cDNA library and preliminary analysis of the expressed sequence tags of the earthworm Eisenia fetida (Savigny, 1826)

Earthworms are useful indicator organisms of soil health and Eisenia fetida have been extensively used as test organisms in ecotoxicological studies. In order to gain insight into the gene expression profiles associated with physiological functions of earthworms, a full-length enriched cDNA library of the Eisenia fetida genome was successfully constructed using Switching Mechanism at 5′End of RNA Template technology. Construction of a cDNA library and analysis of Expressed Sequence Tags (ESTs) are efficient approaches for collecting genomic information and identifying genes important for a given biological process. Furthermore, analysis of the expression abundance of ESTs was performed with the aim of providing genetic and transcriptomic information on the development and regenerative process of earthworms. Phrep and Crossmatch were used to process EST data and a total of 1,140 high-quality EST sequences were determined by sequencing random cDNA clones from the library. Clustering analysis of sequences revealed a total of 593 unique sequences including 225 contiguous and 368 singleton sequences. Basic Local Alignment Search Tool analysis against the Kyoto Encyclopedia of Genes and Genomes database resulted in 593 significant hits (P-value <1×10⁻⁸), of which 168 were annotated through Gene Ontology analysis. The STRING database was used to determine relationships among the 168 ESTs, identifying associated genes involved in protein-protein interactions and gene expression regulation. Based on nucleic acid and protein sequence homology, the mutual relationships between 287 genes could be obtained, which identified a portion of the ESTs as known genes. The present study reports on the construction of a high-quality cDNA library representative of adult earthworms, on a preliminary analysis of ESTs and on a putative functional analysis of ESTs. The present study is expected to enhance our understanding of the molecular basis underlying the biological development of earthworms.

[Clinical analysis of endoscopic endonasal approach for removal of sellar tumors]

Objective:To investigate the safety and efficacy of endoscopic endonasal approach for removal of sellar tumors. Method: The clinical data of 18 patients with sellar tumors undergoing endoscopic endonasal surgery were analyzed retrospectively. This series consisted of ten pituitary adenomas, five craniopharyngiomas, three meningiomas. The headache, visual improvement, endocrine, extent of resection and surgical complications were evaluated. Result:Total removal was achieved in 14 patients (77.8%), almost total removal was achieved in one patient of pituitary adenoma with two craniopharyngiomas (16.7%), and one patient with the subtotal removal of craniopharyngioma (5.6%) received gamma knife therapy. Overall, 18 patients with headache got improved obviously; 15 patients presented with visual and view impairment, All of them, vision and view were improved or even recovered to normal following surgery; There were 2 new cases of postoperative diabetes insipidu; 5(27.8%) patients had hyposmia after operation; 1 patient (5.6%) with adenoma suffered cerebrospinal fluid rhinorrhea, the second operation was successful. The follow-up lasted 12-84 months, no tumor recurrence was identified by MRI examination, and no patient died. Conclusion:The endoscopic endonasal approach is feasible and safe for the treatment of tumors in the sellar region. With advantages of clear vision, better exposure, without brain retraction, and preservation of vascular and neurological function. Skilled endoscopic technique and reliable skull base reconstruction are important to ensure success of surgery.

[Diagnostic efficiency of NO/ET-1 and HCY level in severe OSAHS patients with cognitive impairment]

Objective:To investigate the diagnostic efficiency of HCY and NO/ET-1 to cognitive dysfunction in patients with severe obstructive sleep apnea hypopnea syndrome, and to interfere with the cognitive function of severe OSAHS patients. Method: Eighty-six patients with OSAHS were divided into mild group (22 cases), moderate group (23 cases), severe group (41 cases) and healthy physical examination group (50 cases). The levels of serum HCY and NO/ET-1 were compared between the four groups. The Montreal cognitive assessment scale was used to evaluate the incidence of mild cognitive impairment in severe OSAHS group, and the correlation between the level of serum HCY, NO/ET-1 and cognitive function in severe OSAHS group was analyzed. Result:The level of serum HCY in patients with severe OSAHS with cognitive impairment was(32.28±3.92)μmol/L, higher than that of the cognitive moderate group(26.34±4.05)μmol/L, and mild group (18.62±3.29)μmol/L. The level of serum NO/ET-1 in patients with severe OSAHS with cognitive impairment was (0.69±0.19), higher than that of the cognitive moderate group(2.76±0.28), and mild group (3.98±0.37), the difference was statistically significant (P<0.05). In severe group, there was a negative correlation between the level of serum HCY and the score of MoCA and its subscores (P<0.05), and there was a positive correlation between the total scores of NO/ET-1 and MoCA and their subscores (P<0.05), and negative correlation between HCY and NO/ET-1 (P<0.05). The area under the ROC curve of predicting serum HCY and NO/ET-1 levels in severe OSAHS patients with cognitive impairment were 0.788(95%CI0.654-0.921) and 0.770 (95%CI0.642-0.899). Conclusion:Serum HCY and NO/ET-1 were the factors influencing the formation of cognitive impairment in severe OSAHS patients. The level of HCY was negatively correlated with the degree of cognitive impairment, and NO/ET-1 was positively correlated with the degree of cognitive impairment.

Quantitative research on gas explosion inhibition by water mist

Water mist as an effective explosion inhibitor has wide application prospect to prevent and reduce gas explosion hazard. The quantitative study of gas explosion inhibition with water mist provides the groundwork for the design of gas explosion suppression system. In this paper, the influence of the initial droplet sizes and spraying concentrations on explosion inhibition were numerically studied in a 2D numerical model. Under the initial spraying concentrations in the range of ∼1.5 kg/m³, the inhibition effect of water mist on the explosion overpressure was not significant. The inhibition effect of water mist was mainly reflected in the suppression of the explosion flame temperature. When the initial droplet sizes were in the range of 50-150 μm, the flame length was obviously reduced. But when the initial droplet sizes were less than 50 μm or more than 150 μm, the inhibition to reduce flame length begin to weaken. The results of this study provide the theoretical basis of the suppression technology for gas explosion.

[Effect of modified body position on cVEMP in normal young people]

Objective: To observe the effect of modified body position on cervical vestibular evoked myogenic potential(cVEMP) in normal young people. Method: Thirty normal young people were selected as subjects. CVEMP test was performed by supine head position and sitting submandibular lower body position respectively. The cVEMP examination results were observed and compared. Result: The elicitation rate of the two kinds of position of cVEMP were 100%. There was no significant difference in P1 latency, N2 latency, amplitude and asymmetry ratio. Different body position comfort VAS score, submandibular pressure of sitting position was better than supine head up position(P<0.05). Conclusion: Submandibular pressure of sitting position has no effect on the results of cVEMP examination, and the subjects are more comfortable, and can be used for old age and inability to cooperate with supine head up position.

[Clinical diagnosis and treatment of eosinophilic otitis media]

Objective: Eosinophilic otitis media(EOM) is a rare,refractory otitis media.This article summarizes the clinical manifestations and diagnosis and treatment experience of EOM. Method: Retrospective analysis of 3 cases of EOM patients with medical history, clinical manifestations, and related auxiliary examinations.Discuss the EOM clinical features,diagnosis and treatment in conjunction with the literature. Result: The clinical features of 3 patients with EOM were summarized as: a large amount of yellowish white secretions or polyps formation, obvious itching symptoms; polyp biopsy showed a large amount of eosinophil infiltration;topical use of hormone-containing ear drops treatment is effective.Conclusion: EOM is a new type of chronic otitis media.It has characteristic clinical manifestations,a comprehensive treatment based on glucocorticoids should be given..

Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma

Osteosarcoma (OS) has emerged as the most common primary musculoskeletal malignant tumor which affects children and adolescents. A growing number of relevant studies have shown that many microRNAs (miRNAs) play a vital regulatory role in the etiology of various types of cancer. miR-1258 has been widely studied in various cancers, but there have been few studies of its role in OS. In this present study, miR-1258 expression was dramatically decreased in OS tissues as well as OS cell lines. In addition, decreased expression of miR-1258 was significantly associated with malignant clinical manifestations and poor clinical prognosis of patients with OS. Moreover, upregulation of miR-1258 significantly inhibited cell proliferation as well as promoting cell cycle arrest at G0/G1. AKT3 was identified as a direct target of miR-1258 by binding to its 3'-UTR, and miR-1258 was negatively correlated with AKT3 expression in clinical OS tissues. AKT3 was evidently upregulated in OS tissues and cells and upregulation of AKT3 accelerated the progression of OS. Moreover, through a series of rescue experiments, we demonstrated that AKT3 can abolish the role of miR-1258 in suppressing proliferation as well as regulating the cell cycle in OS cells. In conclusion, our results suggest that the miR-1258-AKT3 axis may be a promising prognostic marker and therapeutic target for human OS.